Fresenius Medical Care AG (NYSE:FMS) Sees Large Decline in Short Interest

Fresenius Medical Care AG (NYSE:FMS) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 683,300 shares, a decline of 8.6% from the September 15th total of 747,500 shares. Based on an average daily volume of 304,500 shares, the short-interest ratio is presently 2.2 days.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. StockNews.com assumed coverage on Fresenius Medical Care in a research report on Tuesday, October 8th. They issued a “strong-buy” rating for the company. Truist Financial boosted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Fresenius Medical Care presently has an average rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Stock Performance

Fresenius Medical Care stock traded up $0.01 on Thursday, hitting $20.04. The company’s stock had a trading volume of 173,597 shares, compared to its average volume of 372,193. The company has a fifty day moving average price of $19.92 and a 200-day moving average price of $20.05. The firm has a market cap of $11.76 billion, a P/E ratio of 22.52, a price-to-earnings-growth ratio of 1.06 and a beta of 0.91. Fresenius Medical Care has a one year low of $16.37 and a one year high of $22.76. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. On average, equities analysts anticipate that Fresenius Medical Care will post 1.52 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after acquiring an additional 758 shares during the period. Uncommon Cents Investing LLC grew its stake in shares of Fresenius Medical Care by 8.0% in the first quarter. Uncommon Cents Investing LLC now owns 38,810 shares of the company’s stock valued at $748,000 after buying an additional 2,890 shares in the last quarter. Legacy Wealth Asset Management LLC acquired a new stake in Fresenius Medical Care in the first quarter valued at $584,000. Veracity Capital LLC increased its stake in shares of Fresenius Medical Care by 172.2% during the 1st quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock worth $1,022,000 after purchasing an additional 33,543 shares during the last quarter. Finally, ORG Partners LLC acquired a new position in Fresenius Medical Care during the first quarter worth approximately $110,000. Institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.